As cancer glycobiologists continue to explore and identify the key glycan structures and the glycan-forming/inhibiting enzymatic machinery of Gal-1, -3, and -9 ligands, there is momentous potential in designing ex vivo-expanded patient T cells, including CAR-T cells, to evade Gal-1, -3, and -9 binding and related immunomodulation. This evidence concerns the gene LGALS1 and cancer.